Catalyst Pharmaceutical Partners, Inc. (CPRX)

Check out top investors' recommendation for CPRX
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
8.00
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. It focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. The company’s principal product includes Firdapse that is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. It also develops CPP-115, a GABA aminotransferase inhibitor for the treatment of epilepsy and other selected central nervous disease indications; and CPP-109 for the treatment of Tourette Syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Charles Duncan Piper Jaffray Buy   Nov 28, '18     8.00  Nov 28, '19  N/A 
Charles Duncan Piper Jaffray Buy   Sep 20, '18     8.00  Sep 20, '19  N/A 
Andrew Fein Chardan Capital Markets Buy   Aug 09, '18     6.00  Aug 09, '19  N/A 
Andrew Fein Chardan Capital Markets Buy   May 30, '18     6.00  May 30, '19  N/A 
Andrew Fein Chardan Capital Markets Buy   Mar 15, '18     6.00  Mar 15, '19  N/A 
Andrew Fein Chardan Capital Markets Buy   Dec 21, '17     6.00  Dec 21, '18  N/A 
Charles Duncan Piper Jaffray Buy   Dec 01, '17     8.00  Dec 01, '18  N/A 
Andrew Fein Chardan Capital Markets Buy   Nov 10, '17     6.00  Nov 10, '18  N/A 
Scott Henry Roth Capital Partners LLC Buy   Nov 01, '17     4.75  Nov 01, '18  N/A 
Edward Nash Cowen And Company Buy   Sep 01, '17     5.00  Sep 01, '18  N/A 
Andrew Fein Chardan Capital Markets Buy   Aug 11, '17     6.00  Aug 11, '18  N/A 
Scott Henry Roth Capital Partners LLC Buy   Aug 10, '17     4.75  Aug 10, '18  N/A 
Charles Duncan Piper Jaffray Buy   Aug 07, '17     6.00  Aug 07, '18  N/A 
Scott Henry Roth Capital Partners LLC Buy   Feb 21, '17     2.50  Feb 21, '18  N/A 
Scott Henry Roth Capital Partners LLC Buy   Oct 15, '16     2.50  Oct 15, '17  N/A 
Jorge Aura Unaffiliated Buy   Mar 06, '16   1.34  1.50  Jun 06, '16  -54.48% 
Scott Henry Roth Capital Partners LLC Buy   Feb 17, '16   1.16  3.25  Feb 17, '17  -3.45% 
Charles Duncan Piper Jaffray Buy   Feb 17, '16   1.16  6.00  Feb 17, '17  -3.45% 
Scott Henry Roth Capital Partners LLC Buy   Aug 12, '15   4.33    Aug 12, '16  -82.68% 
Ram Selvaraju Aegis Capital Buy   Jun 24, '15   4.13    Jun 24, '16  -78.69% 
< previous12